Tocilizumab Monotherapy and Tocilizumab Plus Disease-Modifying Antirheumatic Drugs in a US Rheumatoid Arthritis Population with Inadequate Response to Anti-Tumor Necrosis Factor Agents. Weinblatt, M. E., Kremer, J. M., Cush, J. J., Rigby, W., Teng, L., Singh, N., Malamet, R. L., Genovese, M. C. WILEY-BLACKWELL. 2011: S162

View details for Web of Science ID 000297621500427